Tocris Bioscience Signs Exclusive Deal to Supply Gefitinib for Cancer Research
Tocris Bioscience (Bristol, UK) announced today the signing of an exclusive deal with AstraZeneca to supply Gefitinib (also known as Iressa™ and ZD1839) to preclinical researchers working on the mechanisms underlying cancer development. For the first time, scientists will be able to buy authentic, fully licensed, non-formulated Gefitinib as an off-the shelf product for use in biological research.